VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q104696520 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241121000106.0
008 241121nneanz||abbn n and d
035 ‎‡a (WKP)Q104696520‏
035 ‎‡a (OCoLC)Q104696520‏
100 0 ‎‡a Mark Wansbrough-Jones‏ ‎‡9 en‏ ‎‡9 nl‏
670 ‎‡a Author's Buruli ulcer‏
670 ‎‡a Author's Buruli ulcer disease: prospects for a vaccine‏
670 ‎‡a Author's Buruli ulcer: emerging from obscurity.‏
670 ‎‡a Author's Clearance of viable Mycobacterium ulcerans from Buruli ulcer lesions during antibiotic treatment as determined by combined 16S rRNA reverse transcriptase /IS 2404 qPCR assay.‏
670 ‎‡a Author's Clinical and Bacteriological Efficacy of Rifampin-Streptomycin Combination for Two Weeks followed by Rifampin and Clarithromycin for Six Weeks for Treatment of Mycobacterium ulcerans Disease.‏
670 ‎‡a Author's Combined inflammatory and metabolic defects reflected by reduced serum protein levels in patients with Buruli ulcer disease‏
670 ‎‡a Author's Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial‏
670 ‎‡a Author's Genetic diversity of PCR-positive, culture-negative and culture-positive Mycobacterium ulcerans isolated from Buruli ulcer patients in Ghana‏
670 ‎‡a Author's High prevalence of multidrug-resistant tuberculosis among patients with rifampicin resistance using GeneXpert Mycobacterium tuberculosis/rifampicin in Ghana‏
670 ‎‡a Author's IFN-γ and IL-5 whole blood response directed against mycolactone polyketide synthase domains in patients with infection‏
670 ‎‡a Author's Immunosuppressive signature of cutaneous Mycobacterium ulcerans infection in the peripheral blood of patients with buruli ulcer disease‏
670 ‎‡a Author's Infection with Mansonella perstans Nematodes in Buruli Ulcer Patients, Ghana‏
670 ‎‡a Author's Metabolomic profiles delineate mycolactone signature in Buruli ulcer disease.‏
670 ‎‡a Author's Microbiological, histological, immunological, and toxin response to antibiotic treatment in the mouse model of Mycobacterium ulcerans disease‏
670 ‎‡a Author's Mycobacterium ulcerans Disease: Buruli Ulcer‏
670 ‎‡a Author's Mycobacterium ulcerans infection (Buruli or Bairnsdale ulcer): challenges in developing management strategies‏
670 ‎‡a Author's Mycolactone diffuses into the peripheral blood of Buruli ulcer patients--implications for diagnosis and disease monitoring‏
670 ‎‡a Author's Neglected tropical diseases‏
670 ‎‡a Author's Oral treatment for patients with Buruli ulcer co-infected with HIV: think twice.‏
670 ‎‡a Author's Paradoxical reactions in Buruli ulcer after initiation of antibiotic therapy: Relationship to bacterial load‏
670 ‎‡a Author's Rapid detection of Mycobacterium ulcerans with isothermal recombinase polymerase amplification assay‏
670 ‎‡a Author's Recent advances: role of mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans infection/Buruli ulcer disease.‏
670 ‎‡a Author's Reply to "compliance with antimicrobial therapy for buruli ulcer".‏
670 ‎‡a Author's Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial‏
670 ‎‡a Author's Simple, Rapid Mycobacterium ulcerans Disease Diagnosis from Clinical Samples by Fluorescence of Mycolactone on Thin Layer Chromatography‏
670 ‎‡a Author's Treatment of tuberculosis in HIV-infected individuals‏
919 ‎‡a neglectedtropicaldiseases‏ ‎‡A Neglected tropical diseases‏ ‎‡9 1‏
919 ‎‡a mycolactonediffusesintotheperipheralbloodofburuliulcerpatientsimplicationsfordiagnosisanddiseasemonitoring‏ ‎‡A Mycolactone diffuses into the peripheral blood of Buruli ulcer patients--implications for diagnosis and disease monitoring‏ ‎‡9 1‏
919 ‎‡a mycobacteriumulceransinfectionburuliorbairnsdaleulcerchallengesindevelopingmanagementstrategies‏ ‎‡A Mycobacterium ulcerans infection (Buruli or Bairnsdale ulcer): challenges in developing management strategies‏ ‎‡9 1‏
919 ‎‡a mycobacteriumulceransdiseaseburuliulcer‏ ‎‡A Mycobacterium ulcerans Disease: Buruli Ulcer‏ ‎‡9 1‏
919 ‎‡a microbiologicalhistologicalimmunologicalandtoxinresponsetoantibiotictreatmentinthemousemodelofmycobacteriumulceransdisease‏ ‎‡A Microbiological, histological, immunological, and toxin response to antibiotic treatment in the mouse model of Mycobacterium ulcerans disease‏ ‎‡9 1‏
919 ‎‡a metabolomicprofilesdelineatemycolactonesignatureinburuliulcerdisease‏ ‎‡A Metabolomic profiles delineate mycolactone signature in Buruli ulcer disease.‏ ‎‡9 1‏
919 ‎‡a infectionwithmansonellaperstansnematodesinburuliulcerpatientsghana‏ ‎‡A Infection with Mansonella perstans Nematodes in Buruli Ulcer Patients, Ghana‏ ‎‡9 1‏
919 ‎‡a immunosuppressivesignatureofcutaneousmycobacteriumulceransinfectionintheperipheralbloodofpatientswithburuliulcerdisease‏ ‎‡A Immunosuppressive signature of cutaneous Mycobacterium ulcerans infection in the peripheral blood of patients with buruli ulcer disease‏ ‎‡9 1‏
919 ‎‡a ifnγandil5wholebloodresponsedirectedagainstmycolactonepolyketidesynthasedomainsinpatientswithinfection‏ ‎‡A IFN-γ and IL-5 whole blood response directed against mycolactone polyketide synthase domains in patients with infection‏ ‎‡9 1‏
919 ‎‡a highprevalenceofmultidrugresistanttuberculosisamongpatientswithrifampicinresistanceusinggenexpertmycobacteriumtuberculosisrifampicininghana‏ ‎‡A High prevalence of multidrug-resistant tuberculosis among patients with rifampicin resistance using GeneXpert Mycobacterium tuberculosis/rifampicin in Ghana‏ ‎‡9 1‏
919 ‎‡a geneticdiversityofpcrpositiveculturenegativeandculturepositivemycobacteriumulceransisolatedfromburuliulcerpatientsinghana‏ ‎‡A Genetic diversity of PCR-positive, culture-negative and culture-positive Mycobacterium ulcerans isolated from Buruli ulcer patients in Ghana‏ ‎‡9 1‏
919 ‎‡a effectsofhydroxychloroquineonimmuneactivationanddiseaseprogressionamonghivinfectedpatientsnotreceivingantiretroviraltherapyarandomizedcontrolledtrial‏ ‎‡A Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial‏ ‎‡9 1‏
919 ‎‡a combinedinflammatoryandmetabolicdefectsreflectedbyreducedserumproteinlevelsinpatientswithburuliulcerdisease‏ ‎‡A Combined inflammatory and metabolic defects reflected by reduced serum protein levels in patients with Buruli ulcer disease‏ ‎‡9 1‏
919 ‎‡a clinicalandbacteriologicalefficacyofrifampinstreptomycincombinationfor2weeksfollowedbyrifampinandclarithromycinfor6weeksfortreatmentofmycobacteriumulceransdisease‏ ‎‡A Clinical and Bacteriological Efficacy of Rifampin-Streptomycin Combination for Two Weeks followed by Rifampin and Clarithromycin for Six Weeks for Treatment of Mycobacterium ulcerans Disease.‏ ‎‡9 1‏
919 ‎‡a clearanceofviablemycobacteriumulceransfromburuliulcerlesionsduringantibiotictreatmentasdeterminedbycombined16srrnareversetranscriptaseis2404qpcrassay‏ ‎‡A Clearance of viable Mycobacterium ulcerans from Buruli ulcer lesions during antibiotic treatment as determined by combined 16S rRNA reverse transcriptase /IS 2404 qPCR assay.‏ ‎‡9 1‏
919 ‎‡a buruliulceremergingfromobscurity‏ ‎‡A Buruli ulcer: emerging from obscurity.‏ ‎‡9 1‏
919 ‎‡a buruliulcerdiseaseprospectsforavaccine‏ ‎‡A Buruli ulcer disease: prospects for a vaccine‏ ‎‡9 1‏
919 ‎‡a buruliulcer‏ ‎‡A Buruli ulcer‏ ‎‡9 1‏
919 ‎‡a rapiddetectionofmycobacteriumulceranswithisothermalrecombinasepolymeraseamplificationassay‏ ‎‡A Rapid detection of Mycobacterium ulcerans with isothermal recombinase polymerase amplification assay‏ ‎‡9 1‏
919 ‎‡a recentadvancesroleofmycolactoneinthepathogenesisandmonitoringofmycobacteriumulceransinfectionburuliulcerdisease‏ ‎‡A Recent advances: role of mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans infection/Buruli ulcer disease.‏ ‎‡9 1‏
919 ‎‡a replytocompliancewithantimicrobialtherapyforburuliulcer‏ ‎‡A Reply to "compliance with antimicrobial therapy for buruli ulcer".‏ ‎‡9 1‏
919 ‎‡a rifampicinandclarithromycinextendedreleaseversusrifampicinandstreptomycinforlimitedburuliulcerlesionsarandomisedopenlabelnoninferiorityphase3trial‏ ‎‡A Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial‏ ‎‡9 1‏
919 ‎‡a simplerapidmycobacteriumulceransdiseasediagnosisfromclinicalsamplesbyfluorescenceofmycolactoneonthinlayerchromatography‏ ‎‡A Simple, Rapid Mycobacterium ulcerans Disease Diagnosis from Clinical Samples by Fluorescence of Mycolactone on Thin Layer Chromatography‏ ‎‡9 1‏
919 ‎‡a treatmentoftuberculosisinhivinfectedindividuals‏ ‎‡A Treatment of tuberculosis in HIV-infected individuals‏ ‎‡9 1‏
919 ‎‡a paradoxicalreactionsinburuliulcerafterinitiationofantibiotictherapyrelationshiptobacterialload‏ ‎‡A Paradoxical reactions in Buruli ulcer after initiation of antibiotic therapy: Relationship to bacterial load‏ ‎‡9 1‏
919 ‎‡a oraltreatmentforpatientswithburuliulcercoinfectedwithhivthinktwice‏ ‎‡A Oral treatment for patients with Buruli ulcer co-infected with HIV: think twice.‏ ‎‡9 1‏
996 ‎‡2 NDL|001189898‏
996 ‎‡2 LNB|LNC10-000336712‏
996 ‎‡2 BIBSYS|9005710‏
996 ‎‡2 CAOONL|ncf10469015‏
996 ‎‡2 SUDOC|251135942‏
996 ‎‡2 BIBSYS|1488830535933‏
996 ‎‡2 LC|no2005008108‏
996 ‎‡2 SUDOC|082327068‏
996 ‎‡2 JPG|500232159‏
996 ‎‡2 J9U|987007457475805171‏
996 ‎‡2 BAV|495_349690‏
996 ‎‡2 ISNI|0000000077142665‏
996 ‎‡2 ISNI|0000000070920313‏
996 ‎‡2 LC|no2018015613‏
996 ‎‡2 LC|n 91002141‏
996 ‎‡2 J9U|987007339155505171‏
996 ‎‡2 NUKAT|n 2022200440‏
996 ‎‡2 LC|no2018067175‏
996 ‎‡2 NLA|000035567110‏
996 ‎‡2 LC|n 2015050789‏
996 ‎‡2 LC|no2010136459‏
996 ‎‡2 ISNI|0000000055596471‏
996 ‎‡2 LC|n 88621549‏
996 ‎‡2 DNB|171244230‏
996 ‎‡2 NLA|000035252773‏
996 ‎‡2 J9U|987007404549305171‏
996 ‎‡2 NKC|ola2013750150‏
996 ‎‡2 BNF|13474782‏
996 ‎‡2 ISNI|0000000054505857‏
996 ‎‡2 NTA|128495162‏
996 ‎‡2 DNB|1075549620‏
996 ‎‡2 CAOONL|ncf11194278‏
996 ‎‡2 ISNI|000000008405740X‏
996 ‎‡2 DNB|1268649287‏
996 ‎‡2 SZ|1067414789‏
996 ‎‡2 BNF|16577770‏
996 ‎‡2 ISNI|0000000083631764‏
996 ‎‡2 NUKAT|n 2019005349‏
996 ‎‡2 BNF|15700315‏
996 ‎‡2 BIBSYS|90059304‏
996 ‎‡2 DNB|174002270‏
996 ‎‡2 LC|n 88657896‏
996 ‎‡2 ISNI|0000000043392033‏
996 ‎‡2 RERO|A020140661‏
996 ‎‡2 RERO|A006436500‏
996 ‎‡2 SUDOC|236676415‏
996 ‎‡2 ISNI|0000000114674469‏
996 ‎‡2 BAV|495_349691‏
996 ‎‡2 J9U|987007456475905171‏
996 ‎‡2 LNB|LNC10-000092208‏
996 ‎‡2 BIBSYS|90777083‏
996 ‎‡2 NUKAT|n 98000614‏
996 ‎‡2 NII|DA11724068‏
996 ‎‡2 LC|n 2008053638‏
996 ‎‡2 DNB|10849344X‏
996 ‎‡2 CAOONL|ncf10644797‏
996 ‎‡2 NTA|370173511‏
996 ‎‡2 KRNLK|KAC200807186‏
996 ‎‡2 SUDOC|158185536‏
996 ‎‡2 DNB|1324107413‏
996 ‎‡2 ISNI|0000000115918277‏
996 ‎‡2 DNB|114183317‏
996 ‎‡2 NII|DA00373868‏
996 ‎‡2 NUKAT|n 2009141576‏
996 ‎‡2 LC|n 88009220‏
996 ‎‡2 PTBNP|156705‏
996 ‎‡2 NUKAT|n 2005002451‏
996 ‎‡2 LC|no2021082547‏
996 ‎‡2 LC|n 90605925‏
996 ‎‡2 ISNI|0000000037655175‏
996 ‎‡2 BNF|17148765‏
996 ‎‡2 BIBSYS|11078666‏
996 ‎‡2 BIBSYS|41830‏
996 ‎‡2 N6I|vtls000010735‏
996 ‎‡2 ISNI|0000000383176724‏
996 ‎‡2 BIBSYS|12028681‏
996 ‎‡2 NTA|07508256X‏
996 ‎‡2 ISNI|0000000035910080‏
996 ‎‡2 BAV|495_287887‏
996 ‎‡2 RERO|A009312185‏
996 ‎‡2 LC|nb 99116083‏
996 ‎‡2 LC|nb2021000830‏
996 ‎‡2 J9U|987007460945805171‏
996 ‎‡2 SUDOC|077315804‏
996 ‎‡2 ISNI|0000000101373034‏
996 ‎‡2 DNB|136030645‏
996 ‎‡2 LC|n 88639481‏
996 ‎‡2 ISNI|0000000080595200‏
996 ‎‡2 JPG|500018578‏
996 ‎‡2 LC|nb 99052660‏
996 ‎‡2 BIBSYS|90830440‏
996 ‎‡2 NII|DA07744389‏
996 ‎‡2 BIBSYS|90763725‏
996 ‎‡2 LC|n 88669220‏
996 ‎‡2 J9U|987007315964705171‏
996 ‎‡2 NII|DA17774604‏
996 ‎‡2 NDL|00738888‏
996 ‎‡2 LC|n 96034279‏
996 ‎‡2 LC|n 79058341‏
996 ‎‡2 SUDOC|201071452‏
996 ‎‡2 LC|n 2011080877‏
996 ‎‡2 B2Q|0000014377‏
996 ‎‡2 CAOONL|ncf10642195‏
996 ‎‡2 NII|DA10688548‏
996 ‎‡2 CAOONL|ncf12114972‏
996 ‎‡2 LC|no2019116314‏
996 ‎‡2 ISNI|0000000037293514‏
996 ‎‡2 DNB|1034964887‏
996 ‎‡2 LC|no2019098921‏
996 ‎‡2 LC|n 96054634‏
996 ‎‡2 ISNI|0000000424901823‏
996 ‎‡2 CAOONL|ncf11337428‏
996 ‎‡2 ISNI|0000000051460382‏
996 ‎‡2 ISNI|0000000063684287‏
996 ‎‡2 CAOONL|ncf10075177‏
996 ‎‡2 ISNI|0000000076841085‏
996 ‎‡2 LC|n 85080076‏
996 ‎‡2 LC|n 50007165‏
996 ‎‡2 ISNI|0000000463376240‏
996 ‎‡2 LC|n 2013004326‏
996 ‎‡2 NTA|32208895X‏
996 ‎‡2 NUKAT|n 2017196870‏
996 ‎‡2 NDL|01203015‏
996 ‎‡2 NTA|138257639‏
996 ‎‡2 NTA|269084975‏
996 ‎‡2 NTA|394186389‏
996 ‎‡2 BIBSYS|8022533‏
996 ‎‡2 NII|DA17079796‏
996 ‎‡2 ISNI|0000000043076911‏
996 ‎‡2 DNB|1344166563‏
996 ‎‡2 LC|n 2008020038‏
996 ‎‡2 SUDOC|19188295X‏
996 ‎‡2 RERO|A011108745‏
996 ‎‡2 RERO|A022568544‏
996 ‎‡2 BIBSYS|4025693‏
996 ‎‡2 NTA|315548827‏
996 ‎‡2 DBC|87097961864644‏
996 ‎‡2 LC|nb2010026883‏
996 ‎‡2 BIBSYS|1592544498297‏
996 ‎‡2 NSK|000093105‏
996 ‎‡2 BLBNB|001574256‏
996 ‎‡2 ISNI|0000000394408105‏
996 ‎‡2 J9U|987007376397105171‏
996 ‎‡2 ISNI|0000000043232857‏
996 ‎‡2 LC|n 89605411‏
996 ‎‡2 SUDOC|113639481‏
996 ‎‡2 LC|no 97053865‏
996 ‎‡2 CAOONL|ncf10643911‏
996 ‎‡2 BNF|17142372‏
996 ‎‡2 J9U|987007269530505171‏
996 ‎‡2 LC|n 95041174‏
996 ‎‡2 NTA|160438004‏
996 ‎‡2 LC|no2009013249‏
996 ‎‡2 NKC|stk2007383196‏
996 ‎‡2 CAOONL|ncf10706951‏
996 ‎‡2 DNB|136030734‏
996 ‎‡2 SUDOC|16975023X‏
996 ‎‡2 BNE|XX1218703‏
996 ‎‡2 NII|DA18724394‏
996 ‎‡2 NTA|29748897X‏
996 ‎‡2 LC|no2003047800‏
996 ‎‡2 ISNI|0000000054789773‏
996 ‎‡2 LC|no 98079363‏
996 ‎‡2 ISNI|0000000401925144‏
996 ‎‡2 BIBSYS|90898503‏
996 ‎‡2 BNF|15004020‏
996 ‎‡2 LC|no2017111007‏
996 ‎‡2 BIBSYS|14006639‏
996 ‎‡2 LC|n 92043333‏
996 ‎‡2 BNF|16775415‏
996 ‎‡2 SIMACOB|269465699‏
996 ‎‡2 BNF|12093191‏
996 ‎‡2 BIBSYS|1022102‏
996 ‎‡2 ISNI|0000000051309818‏
996 ‎‡2 DNB|1041836074‏
996 ‎‡2 ISNI|0000000133567095‏
996 ‎‡2 NUKAT|n 2017076429‏
996 ‎‡2 J9U|987007430259805171‏
996 ‎‡2 LC|no2024096105‏
996 ‎‡2 BIBSYS|1707990462809‏
996 ‎‡2 RERO|A027655582‏
996 ‎‡2 LC|no 89012112‏
996 ‎‡2 BNF|18174793‏
996 ‎‡2 NSK|000667105‏
996 ‎‡2 LC|nb2014003939‏
996 ‎‡2 DNB|14263168X‏
996 ‎‡2 DNB|1122069405‏
996 ‎‡2 LC|nb2006021595‏
996 ‎‡2 BIBSYS|14016693‏
996 ‎‡2 LC|nb2013017681‏
996 ‎‡2 BIBSYS|3030556‏
996 ‎‡2 LC|n 2012074913‏
996 ‎‡2 CAOONL|ncf12120847‏
996 ‎‡2 SUDOC|167412876‏
996 ‎‡2 BIBSYS|1542227323818‏
996 ‎‡2 J9U|987007414680405171‏
996 ‎‡2 DNB|1079912088‏
996 ‎‡2 JPG|500271122‏
996 ‎‡2 BIBSYS|90524019‏
996 ‎‡2 ISNI|0000000402660213‏
996 ‎‡2 NTA|41110859X‏
996 ‎‡2 LC|nb2005015990‏
996 ‎‡2 LC|no2024037172‏
996 ‎‡2 LC|n 87878884‏
996 ‎‡2 NKC|jn20000605116‏
996 ‎‡2 ISNI|0000000463376232‏
996 ‎‡2 ISNI|0000000038197540‏
996 ‎‡2 DNB|1138949566‏
996 ‎‡2 LC|n 78078704‏
996 ‎‡2 LC|no2005009091‏
996 ‎‡2 DNB|1193435943‏
996 ‎‡2 LC|nb2002017659‏
996 ‎‡2 BIBSYS|2122154‏
996 ‎‡2 ISNI|0000000116623278‏
996 ‎‡2 ERRR|12520469‏
996 ‎‡2 NUKAT|n 2015094179‏
996 ‎‡2 SUDOC|227531825‏
996 ‎‡2 ISNI|0000000039853773‏
996 ‎‡2 J9U|987007384411405171‏
996 ‎‡2 ISNI|0000000043735083‏
996 ‎‡2 J9U|987007586337205171‏
996 ‎‡2 NUKAT|n 2007117996‏
996 ‎‡2 ISNI|0000000036897412‏
996 ‎‡2 NTA|21580919X‏
996 ‎‡2 ISNI|0000000116310773‏
996 ‎‡2 B2Q|0000034483‏
996 ‎‡2 BNE|XX888583‏
996 ‎‡2 NII|DA06032702‏
996 ‎‡2 DNB|1120543150‏
996 ‎‡2 NUKAT|n 2012168454‏
996 ‎‡2 BNF|17148758‏
996 ‎‡2 NII|DA13164598‏
996 ‎‡2 RERO|A027632046‏
996 ‎‡2 LC|no2024114668‏
996 ‎‡2 LC|n 96803486‏
996 ‎‡2 ISNI|0000000054262760‏
996 ‎‡2 CAOONL|ncf10376058‏
996 ‎‡2 LC|n 89225316‏
996 ‎‡2 BAV|495_124406‏
996 ‎‡2 J9U|987007270085005171‏
996 ‎‡2 ISNI|0000000074369362‏
996 ‎‡2 ISNI|0000000073606629‏
996 ‎‡2 LC|nb2015014459‏
996 ‎‡2 SUDOC|169842568‏
996 ‎‡2 NKC|xx0249012‏
996 ‎‡2 LC|n 90628354‏
996 ‎‡2 LC|no2013142611‏
996 ‎‡2 LC|n 2012035307‏
996 ‎‡2 DNB|1067414789‏
996 ‎‡2 NTA|134225074‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏